Next-generation cancer vaccines and emerging immunotherapy combinations
Cet article passe en revue les vaccins anticancéreux de nouvelle génération ainsi que les stratégies thérapeutiques combinant ces vaccins avec les inhibiteurs de point de contrôle immunitaire ou les thérapies cellulaires
The advent of new technologies has made it possible to discover new tumour-specific antigens, including those with (modified) wild-type amino acid sequences, and to predict their immunogenic potential for the generation of more efficient cancer vaccines. New cancer vaccine platforms have been designed with self-adjuvant, stable and immunogenic properties, thus leading to higher cancer vaccine efficacy. mRNA vaccines represent an easy-to-manufacture and cost-sparing vaccine type. Combination of immune checkpoint inhibitors with cancer vaccines has been shown to generate clinical benefits for a group of patients with various malignancies. Cellular therapies may benefit from being combined with cancer vaccines, especially in the case of solid malignancies.
Trends in Cancer , résumé, 2023